Clinical Trial Update: Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial studied the combination of palbociclib and binimetinib in patients with advanced KRAS-mutant non-small cell lung cancer; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED